A cura do cancao a-o poumon a depende da tanti fattoî, compreiso o stadio do cancao, o tipo de cancao a-o poumon e a sanitæ generale do paçiente.
Çerte opçioin de trattamento commun includdan:
1. Chirurgia: sto chì de spesso o l'é o trattamento ciù avvoxou pe-o cancao a-o polmon in fase primma.
O chirurgo o leva o tumô e unna picciña porçion de tesciuo san ch'o gh'é d'in gio.
2. terapia de radiaçioin: e radiaçioin de erta energia vëgnan deuviæ pe ammassâ e çellole do cancao e redue i tumori.
O peu ëse deuviou da solo ò in combinaçion con di atri trattamenti.
3. chemioterapia: sto tratamento o deuvia de mëxiñe pe ammassâ e çellole do cancao.
O peu ëse dæto pe via intravenosa ò pe via orale, e o ven deuviou de spesso in combinaçion con di atri trattamenti.
4. Terapia mirâ: sta terapia a l'ammia a-i geni ò a-e proteiñe speçifeghe che contribuiscian a-a crescita e a-a sopravivensa de çellole do cancao.
O ven deuviou de spesso pe-o cancao do polmon avansou ò metastatico.
5. Immunoterapia: sto trattamento o l'aggiutta o scistema immunitäio à reconosce e attaccâ e çellole do cancao.
O ven deuviou de spesso pe-o cancao do polmon avansou ò metastatico.
6. Terapia fotodinamica: sto tratamento o deuvia un farmaco attivou da-a luxe pe ammassâ e çellole do cancao.
O l"é deuviou de spesso pe-o cancao a-o prinçipio do cancao.
7. terapia di protoni: sto chì o l"é un tipo de terapia de radiaçion ch'a deuvia di protoni incangio di raggi x pe dâ radiaçion a-o tumô.
O l"é deuviou de spesso pe-o cancao a-o prinçipio do cancao.
8. preuva clinica: I paçienti peuan ëse boin à parteçipâ à de preuva cliniche pe testâ de neuve terapie ò de combinaçioin de terapie.
L'é importante discutte e megio opçioin de trattamento con un gruppo de sanitæ, perché o cian de trattamento ciù efficace o depende da-a scituaçion particolâ de l'individuo.
Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.
Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.
Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.
Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.
Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.
Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.
Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.
['Disclaimer: medicâ']
["Sto scito web o l'é fornio solo pe di propòxiti educativi e informativi e o no costituisce un conseggio medico ò serviççi profescionæ."]
["L'informaçion fornia a no dovieiva ëse deuviâ pe diagnosticâ ò curâ un problema de sanitæ ò unna mouttia, e quelli che çercan un conseggio medico personale devan consultâ un mego licençiou."]
['Pe piaxei, ti ti o sæ che a ræ neurale ch\'a genera de respòste a-e domande a l"é inprecisa sorviatutto quande se tratta de contegnui numerichi, comme o numero de persoñe che gh\'é stæto diagnosticou unna mouttia particolâ.']
["çercâ delongo o conseggio do teu mego ò de un atro fornitô de sanitæ qualificou in sciâ condiçion medica. no trascurâ mai o conseggio de un mego profescionista ò ritardâ a çercâlo apreuvo à quarcösa che ti t'æ lezuo in sce sto scito web."]
['Disclaimer: copyright']
["O Digital Millennium Copyright Act do 1998, 17 U.S.C. § 512 (o DMCA) o fornisce un ricorso pe-i propietäi de copyright che creddan che o materiale ch'o l'appare in sce Internet o l'infrange i seu driti segondo a leze di copyright di Stati Unii. "]
["Se ti ti creddi de bonn-a fede che un qualunque contegnûo ò materiale misso a dispoxiçion in connescion co-o nòstro scito web ò serviççi o l'infrange i teu driti d'autô, ti (ò o teu agente) ti peu mandâne 'na notifica con domandâ che o contegnûo ò o materiale o segge levòu ò che l'acesso o segge bloccou."]
['E comunicaçioin devan vegnî mandæ pe iscritto pe email (veddi a seçion "Contact" pe l\'indirissô email).']
["O DMCA o l'exige che a teu notifica de presunta violaçion di driti d'autô a contégne e informaçioìn chi sótta: (1) descriçion de l'euvia protetta da driti d'autô ch'a l'é l'oggetto da presunta violaçion; (2) descriçion do contegnûo che se presumibilmente o l'é a violaçion e informaçioìn suffiçienti pe permette a niatri de localizzâlo; (3) informaçioìn de contatto pe ti, compreiso o teu indirìsso, o teu nómme de telefonin e o teu indirìsso email; (4) 'na teu affermaçion che ti ti credi de bonn-a fêde che o contegnûo into mòddo reclamòu o no segge autorizòu da-o propietâio di driti d'autô, ò da-o seu agente, ò da l'açion de quæ se segge leze; "]
["(5) unna declaraçion da parte teu, firmâ sotta pena de perjurio, che e informaçioin inta notifica son accuræ e che ti gh'æ l'autoritæ de fâ respettâ i driti d'autô che se sostegne che seggian stæti violati;"]
["e (6) unna firma fixica ò elettrònica do propietäio do drito d'autô ò de unna persoña autorisâ à agî a-o seu nomme."]
["Se no ti inserisci tutte e informaçioin chì de d'ato, o peu comportâ un retardo into trattamento da teu lamentela."]
['Contatto']
["Pe piaxei manda 'na mail con ògni domanda/suggerimento."]
How to treat lung cancer?
The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.
Some common treatment options include:
1. Surgery: This is often the preferred treatment for early-stage lung cancer.
The surgeon removes the tumor and a small portion of healthy tissue around it.
2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.
It can be used alone or in combination with other treatments.
3. Chemotherapy: This treatment uses drugs to kill cancer cells.
It can be given intravenously or or orally, and is often used in combination with other treatments.
4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.
It is often used for advanced or metastatic lung cancer.
5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.
It is often used for advanced or metastatic lung cancer.
6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.
It is often used for early-stage lung cancer.
7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.
It is often used for early-stage lung cancer.
8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.
It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['In sciâ']
['BioMedLib o deuvia di computer automatizzæ (algoritmi de machine learning) pe generâ de cobbie de domande e respòste.']
['Comensemmo con 35 mioin de pubricaçioin biomediche de PubMed/Medline.']
